Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology iptacopan - CFB inhibitor Appendix Innovation: Clinical trials Neuroscience Oncology iptacopan - CFB inhibitor References Abbreviations Other NCT03955445 (CLNP023B12001B) NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 Indication C3 glomerulopathy (C3G) Indication Phase Phase 2 Phase Patients 27 patients from ongoing Ph2 (sample size from Ph3 pending HA discussions Q1 2021), total patients for this study will increase Patients 68 Primary Outcome Measures Arms Intervention Target Patients Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy Primary Outcome Measures Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Experimental: iptacopan 200mg b.i.d. Patients with native C3G Arms Intervention Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Target Patients Readout Milestone(s) 2025 Readout Milestone(s) Publication 2023 TBD Publication Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 47 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation